Clinical Trials Logo
  1. Home
  2. Urothelial Carcinoma Bladder
  3. NCT05241340

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer — RAD-VACCINE  

Urothelial Carcinoma Bladder Clinical Trial

Official title:
A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Clinical Trial Summary

This is a prospective, single-institution, single-arm, phase II clinical trial that tests a novel strategy of neoadjuvant Sasanlimab, an immune checkpoint inhibitor (ICI), in combination with stereotactic body radiation therapy as an in-situ vaccination in patients, who are ineligible to receive cisplatin-based chemotherapy and undergoing radical cystectomy for muscle-invasive bladder cancer.

Clinical Trial Description

Patients with cT2-T4a, N0, M0 urothelial bladder carcinoma (UBC) after transurethral resection of the bladder will receive 2 doses of sasanlimab (PF-06801591) at the dose of 300mg subcutaneously, followed by 3 doses of radiation (8Gy x 3) prior to surgery (radical cystectomy). Cystectomy will be planned to be done within 6 weeks of the last dose of sasanlimab. Pathologic complete response (pT0) is the primary endpoint, in addition to a safety lead-in endpoint consisting of a composite outcome of feasibility and safety. Exploratory biomarker analysis on tissue/blood samples will include genomic and immune-system profiling in tumor and blood before and after sasanlimab/radiation therapy, and after radical cystectomy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05241340
Study type Interventional
Source The Methodist Hospital Research Institute
Contact Maryam Anis
Phone 3462386123
Email manis2@houstonmethodist.org
Status Recruiting
Phase Phase 2
Start date February 15, 2022
Completion date August 1, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03606174 - A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma Phase 2
Recruiting NCT05839119 - Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant Phase 1
Completed NCT03558503 - A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Phase 2
Completed NCT05136898 - Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) Phase 3
Withdrawn NCT06090318 - Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Phase 1/Phase 2
Recruiting NCT03185468 - Intervention of Bladder Cancer by CAR-T Phase 1/Phase 2
Active, not recruiting NCT05243550 - A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Phase 3
Recruiting NCT05312671 - Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Phase 2
Recruiting NCT02951325 - Bladder Cancer Adjuvant Radiotherapy Trial N/A
Recruiting NCT05375903 - A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Phase 1
Recruiting NCT05401279 - Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer Phase 2
Active, not recruiting NCT04386746 - Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT06184516 - Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy Phase 2
Not yet recruiting NCT06331299 - A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer Phase 3
Not yet recruiting NCT05656235 - Renal Retention in High Grade Upper Tract Urothelial Cancer Phase 2
Not yet recruiting NCT05037279 - Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Phase 3
Terminated NCT04688931 - A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Phase 3
Recruiting NCT05077709 - IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Phase 2
Completed NCT04200963 - A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Phase 1
Recruiting NCT04770974 - Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic